跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2013-001744-65-DE
EUCTR2013-001744-65-DE进行中（未招募）1 期

A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Paediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acute and Maintenance Phases

Shire Development LLC0 个研究点目标入组 107 人开始时间: 2017年2月20日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
107
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Ability to voluntarily provide written, signed, and dated (personally or via a LAR) informed consent or assent as applicable to participate in the study.
  • •2. Subject’s parent/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures and restrictions.
  • •3. Male and female children and adolescents aged 5-17 years, inclusive, at the Baseline Visit (Visit 2).
  • •4. Body weight 18-90kg at the Screening Visit (Visit 1) and the Baseline Visit (Visit 2).
  • •5. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.
  • •6. Diagnosed with mild to moderate UC, established by sigmoidoscopy or colonoscopy with compatible histology. Screened subjects may also have an unconfirmed diagnosis of mild to moderate UC; however the diagnosis of mild to moderate UC must have been
  • •established by sigmoidoscopy or colonoscopy with compatible histology prior to the Baseline Visit (Visit 2).
  • •7. Subject is able to swallow the investigational product whole.
  • •Double-blind Acute Phase:
  • •8. Partial UC-DAI score =2 (with a combined rectal bleeding and stool frequency score =1 and PGA=1 or 2) and with mucosal appearance (endoscopy score)=2 or 3 at the Baseline Visit (Visit 2), for which 5-ASA would be used as part of normal treatment.
  • •9. If the subject is on 5-ASA treatment prior to study entry, then the dose must be stable. Stable therapy is defined as no change in dose, or no initiation of 5-ASA, from the onset of the current acute flare through discontinuation of therapy (required at the Baseline
  • •Visit; Visit 2). See exclusion criterion 28 for an additional 5-ASA dose-related requirement.
  • •Double-blind Maintenance Phase:
  • •10. Partial UC-DAI =1 (with rectal bleeding=0 and stool frequency =1 and PGA=0) and with mucosal appearance (endoscopy score)=0 or 1 at the Baseline Visit (Visit 2).
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 128
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1. Severe UC (defined by PGA=3) at the Baseline Visit (Visit 2).
  • •2. Crohn’s disease, bleeding disorders, active peptic ulcer disease
  • •3. Asthma, only if known to be 5-ASA sensitive.
  • •4. Positive stool culture for enteric pathogens (including Salmonella, Shigella, Yersina, Aeromonas, Plesiomonas, or Campylobacter). Clostridium difficile toxin, ova, or parasites present.
  • •5. Previous colonic surgery.
  • •6. History of hepatic impairment, in the opinion of the investigator.
  • •7. Moderate to severe renal impairment, in the opinion of the investigator
  • •8. Immediate or significant risk of toxic megacolon, in the opinion of the investigator.
  • •9. History of pancreatitis.
  • •10. History of Reyes syndrome.
  • •11. Systemic or rectal corticosteroid use within 4 weeks prior to the Screening Visit (Visit 1). Topical, intranasal, or inhaled use is not exclusionary.
  • •12. Immunomodulator (eg, 6-mercaptopurine, azathioprine) use within 6 weeks prior to the Screening Visit (Visit 1).
  • •13. History of biologic (eg, anti-tumor necrosis factor agents, integrin receptor antagonists) within 1 year prior to the Screening Visit (Visit 1).
  • •14. Antibiotic use within 7 days prior to the Screening Visit (Visit 1).
  • •15. Any anti-inflammatory drugs, not including 5-ASA treatment but including non-steroidal anti-inflammatory drugs such as aspirin, COX-2 inhibitors or ibuprofen, within 7 days prior to the Screening Visit (Visit 1) unless used at over the counter levels for <3 days. However, prophylactic use of a stable dose of aspirin up to 325mg/day for cardiac disease is permitted.
  • •16. Oral anticoagulant use (with the exception of subjects who have been on a stable dose of Vitamin K antagonists such as warfarin for at least 90 days prior to the Screening Visit [Visit 1] and who are medically stable).
  • •17. Treatment with anti-diarrheals and/or anti-spasmodics within 3 days prior to the Screening Visit (Visit 1).
  • •18. Vaccination/immunization within 21 days prior to the Screening Visit (Visit 1).
  • •19. Predisposed to the development of myo- or pericarditis.
  • •20. Previously been randomized into this study and withdrawn.
  • •21. Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or could affect clinical or laboratory assessments.
  • •22. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment, including surgery, or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
  • •23. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied, or could affect the action, absorption, or disposition of the investigational product(s), or clinical or laboratory assessment. (Current use is defined as use within 21 days of the Screening Visit [Visit 1], or pharmacokinetic equivalent of 5 half-lives, whichever is longer.) See Section 5 (Prior and Concomitant Treatment) for a list of prohibited and restricted
  • •medications.
  • •24. Known or suspected intolerance or hypersensitivity to the investigational product(s) (aminosalicylates eg, 5-ASA), closely related compounds (including but not limited to salicylates), or any of the stated ingredients.
  • •25. Known history of alcohol or other substance abuse within the last year.
  • •26. Within 30 days prior to the first dose of investigational product:

研究者

相似试验

进行中（未招募）
1 期
A clinical trial which compares the effectiveness and safety of a not yet approved drug, called S-033188, versus placebo, and versus an approved drug (Oseltamivir) for 5 Days in Patients with Influenza at High Risk of Influenza ComplicationsInfluenza
EUCTR2016-002688-32-BGShionogi Ltd.2,157
进行中（未招募）
1 期
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)
EUCTR2018-002630-21-BECidara Therapeutics Inc.218
进行中（未招募）
1 期
A clinical trial to investigate the safety and effectiveness of MMX Mesalamine/mesalazine in Children and Adolescents aged 5-17 years who have mild to moderate Ulcerative ColitisMild to Moderate Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
EUCTR2013-001744-65-HUShire Devlopment LLC107
进行中（未招募）
1 期
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Comparator (Clindamycin or Vancomycin) for the Treatment of Complicated Skin and Skin Structure Infections, Including Those due to MRSA, in Pediatric Subjects Ages 8 to 17 Years OldComplicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA)MedDRA version: 9.1 Level: LLT Classification code 10040872 Term: Skin infectionMedDRA version: 9.1 Level: LLT Classification code 10066409 Term: Staphylococcal skin infectionMedDRA version: 9.1 Level: LLT Classification code 10066412 Term: Staphylococcal aureus skin infection
EUCTR2008-001936-11-GBWyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company400
进行中（未招募）
1 期
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Comparator (Clindamycin or Vancomycin) for the Treatment of Complicated Skin and Skin Structure Infections, Including Those due to MRSA, in Pediatric Subjects Ages 8 to 17 Years OldComplicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA)MedDRA version: 9.1Level: LLTClassification code 10040872Term: Skin infectionMedDRA version: 9.1Level: LLTClassification code 10066409Term: Staphylococcal skin infectionMedDRA version: 9.1Level: LLTClassification code 10066412Term: Staphylococcal aureus skin infection
EUCTR2008-001936-11-BEWyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company400